Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Authors
Van Cutsem, EYoshino, T
Lenz, H
Lonardi, S
Falcone, A
Limón, M
Saunders, Mark P
Sobrero, A
Park, Y
Ferreiro, R
Hong, Y
Tomasek, J
Taniguchi, H
Ciardiello, F
Stoehr, J
Oum'Hamed, Z
Vlassak, S
Studeny, M
Argiles, G
Affiliation
Division of Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, BelgiumIssue Date
2018-07-13
Metadata
Show full item recordAbstract
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies.Citation
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. 2018, Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdy241PubMed ID
30010751Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy241